Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $33,302.99 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Monday, July 6th, Luke Evnin sold 35,770 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.32, for a total transaction of $11,446.40.
• On Tuesday, June 9th, Luke Evnin sold 76,928 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $28,463.36.
• On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $24,218.80.
• On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total value of $9,978.40.
• On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.44, for a total value of $8,831.68.
• On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $12,494.58.
• On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $13,317.75.
• On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
• On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total value of $12,741.08.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $0.40 on Friday. The stock has a market capitalization of $19.59 million, a PE ratio of -0.32 and a beta of 0.30. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $2.38. The company has a 50 day moving average price of $0.44 and a 200-day moving average price of $0.63.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HOWL. Susquehanna International Group LLP increased its holdings in shares of Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the last quarter. Regal Investment Advisors LLC increased its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the second quarter valued at approximately $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on HOWL shares. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.